DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: corticotropin
Summary for Generic Name: corticotropin
| |||||||||||
Clinical Trials for: corticotropinActhar for Treatment of Proteinuria in Diabetic Nephropathy Patients Status: Recruiting Condition: Diabetic Nephropathy Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Status: Recruiting Condition: Proteinuria; Idiopathic Membranous Nephropathy Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Status: Recruiting Condition: Systemic Lupus Erythematosus (SLE) A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines Status: Recruiting Condition: Chronic Migraine Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes Status: Completed Condition: Nephrotic Syndromes Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Status: Completed Condition: Treatment Resistant Nephrotic Syndrome Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Status: Recruiting Condition: Lupus Erythematosus Systemic Exacerbation Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency Status: Completed Condition: Adrenal Gland Hyperfunction; Adrenal Gland Hypofunction; Cushing's Syndrome; Healthy A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Status: Active, not recruiting Condition: Glomerulonephritis Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone Status: Terminated Condition: Multiple Sclerosis Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon | CORTROPHIN-ZINC | corticotropin-zinc hydroxide | Injectable; Injection | 009854 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aventis | ACTHAR | corticotropin | Injectable; Injection | 007504 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organics Lagrange | CORTICOTROPIN | corticotropin | Injectable; Injection | 010831 | Approved prior to Jan 1, 1982 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organon | PURIFIED CORTROPHIN GEL | corticotropin | Injectable; Injection | 008975 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc